Sugita K, Okui M, Taguchi N, Miyauchi J
Department of Pediatrics, National Children's Hospital, Tokyo.
Rinsho Ketsueki. 1992 Mar;33(3):349-53.
In a 4-year-old girl having acute megakaryoblastic leukemia, recombinant human granulocyte colony-stimulating factor (G-CSF) was used in combination with chemotherapy for remission induction after the second relapse of her leukemia. G-CSF was given intravenously at a dose of 100 micrograms/m2/day 24 hours prior to chemotherapy until the peripheral neutrophil counts fully recovered. Cytosine arabinoside (Ara-c) [100mg/m2/day] and VP-16 [100mg/m2/day] were given from day 1 through day 10. Her leukemia was resistant to chemotherapy alone after the second relapse but complete remission and hematological recovery were achieved two months after the start of this therapy. Although in vitro clonal assay did not show significant stimulation of colony formation by G-CSF on leukemia cells of this patient, and the mechanism underlying remission induction by this combination therapy remains unclear, it may be of benefit to use G-CSF in combination with chemotherapy for patients with drug-resistant leukemia.
在一名患有急性巨核细胞白血病的4岁女童中，重组人粒细胞集落刺激因子（G-CSF）在其白血病第二次复发后与化疗联合用于诱导缓解。在化疗前24小时静脉给予G-CSF，剂量为100微克/平方米/天，直至外周中性粒细胞计数完全恢复。从第1天至第10天给予阿糖胞苷（Ara-c）[100毫克/平方米/天]和依托泊苷（VP-16）[100毫克/平方米/天]。她的白血病在第二次复发后对单纯化疗耐药，但在该治疗开始两个月后实现了完全缓解和血液学恢复。尽管体外克隆试验未显示G-CSF对该患者白血病细胞的集落形成有明显刺激作用，且这种联合治疗诱导缓解的潜在机制仍不清楚，但对于耐药白血病患者，将G-CSF与化疗联合使用可能有益。
